A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

Dennis L. Citrin, Merrill S. Kies, Carl‐Bertil ‐B Wallemark, Jan Khandekar, Edward Kaplan, Fernando J. Camacho, Richard Lind

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

Original languageEnglish (US)
Pages (from-to)457-460
Number of pages4
JournalCancer
Volume56
Issue number3
DOIs
StatePublished - Jan 1 1985

Fingerprint

Prostatic Neoplasms
Estrogens
Hormones
Therapeutics
fosfestrol

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. / Citrin, Dennis L.; Kies, Merrill S.; Wallemark, Carl‐Bertil ‐B; Khandekar, Jan; Kaplan, Edward; Camacho, Fernando J.; Lind, Richard.

In: Cancer, Vol. 56, No. 3, 01.01.1985, p. 457-460.

Research output: Contribution to journalArticle

Citrin, Dennis L. ; Kies, Merrill S. ; Wallemark, Carl‐Bertil ‐B ; Khandekar, Jan ; Kaplan, Edward ; Camacho, Fernando J. ; Lind, Richard. / A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. In: Cancer. 1985 ; Vol. 56, No. 3. pp. 457-460.
@article{e1b40addd22b45f98a9d193da7b03fb3,
title = "A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer",
abstract = "Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17{\%}, while 22{\%} of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40{\%}). Thromboembolic complications were seen in 2 (8{\%}). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.",
author = "Citrin, {Dennis L.} and Kies, {Merrill S.} and Wallemark, {Carl‐Bertil ‐B} and Jan Khandekar and Edward Kaplan and Camacho, {Fernando J.} and Richard Lind",
year = "1985",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7",
language = "English (US)",
volume = "56",
pages = "457--460",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer

AU - Citrin, Dennis L.

AU - Kies, Merrill S.

AU - Wallemark, Carl‐Bertil ‐B

AU - Khandekar, Jan

AU - Kaplan, Edward

AU - Camacho, Fernando J.

AU - Lind, Richard

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

AB - Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.

UR - http://www.scopus.com/inward/record.url?scp=0021840733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021840733&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

DO - 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7

M3 - Article

VL - 56

SP - 457

EP - 460

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -